Colonial Trust’s Haemonetics HAE Stock Holding History

Colonial Trust’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$78	–	1196
2024 Q4	$78	Buy	+1	New	+$80	﹤0.01%	1316

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.82B AUM 7.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Colonial Trust's HAE Position: Q1 2025 in Review

Colonial Trust sold out of Haemonetics (HAE) in Q1 2025, closing a stake of 1 share — an estimated $78 sold.

Colonial Trust first reported a position in HAE in Q4 2024 and held it in 1 quarter. The position peaked at $78 in Q4 2024. 314 funds tracked by Wall St. Rank hold HAE as of Q1 2025.

Colonial Trust reported no remaining Haemonetics position as of Q1 2025 after selling out during the quarter.
Colonial Trust sold 1 Haemonetics share in Q1 2025, an estimated $78.
Colonial Trust first reported a position in Haemonetics in Q4 2024 and held it in 1 quarter.
Colonial Trust's Haemonetics position peaked at $78 in Q4 2024.
314 funds tracked by Wall St. Rank held Haemonetics as of Q1 2025.

Based on Colonial Trust's 13F filing for Q1 2025, filed 14 May 2025.